You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Multiple Antigen Specific Endogenously derived T cells

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Malignant Melanoma Trial in Herlev (Cyclophosphamide, Fludarabine Phosphate, Multiple Antigen Specific Endogenously derived T

Recruiting
  • Malignant Melanoma
  • Herlev, Denmark
    National Center for Cancer Immune Therapy (CCIT-DK)
Sep 14, 2021

Multiple Myeloma Trial in New York (drug, biological, procedure)

Active, not recruiting
  • Multiple Myeloma
  • New York, New York
    Memorial Sloan Kettering Cancer Center
Jan 3, 2023

Antigen-specific T Cells in Antisynthetase Syndrome and

Not yet recruiting
  • Antisynthetase Syndrome
  • BAL antigen-specific Th1 cells and Th17 cells, ILC and MAIT
  • Dijon, France
  • +5 more
Aug 2, 2023

Acute Myeloid Leukemia, Myelodysplastic Syndrome Trial in Houston (MultiTAA-specific T cells)

Recruiting
  • Acute Myeloid Leukemia
  • Myelodysplastic Syndrome
  • MultiTAA-specific T cells
  • Houston, Texas
  • +1 more
May 31, 2022

Refractory Multiple Myeloma, Relapsed Multiple Myeloma Trial in San Francisco (Manufactured Anti-BCMA CAR-T cells, Fludarabine,

Recruiting
  • Refractory Multiple Myeloma
  • Relapsed Multiple Myeloma
  • Manufactured Anti-BCMA CAR-T cells
  • +2 more
  • San Francisco, California
    University of California, San Francisco
Jan 6, 2023

Multiple Myeloma Trial in Houston (TAA-specific CTLs, TAA-specific CTLs- fixed dose)

Recruiting
  • Multiple Myeloma
  • TAA-specific CTLs
  • TAA-specific CTLs- fixed dose
  • Houston, Texas
    Houston Methodist Hospital
Nov 11, 2022

Leukemia, Acute Lymphoblastic Leukemia Trial in New York (gene-modified T cells targeted)

Active, not recruiting
  • Leukemia
  • Acute Lymphoblastic Leukemia
  • gene-modified T cells targeted
  • New York, New York
    Memorial Sloan Kettering Cancer Center
Feb 1, 2023

Prostate Cancer Trial in New York (engineered autologous T cells, cyclophosphamide)

Active, not recruiting
  • Prostate Cancer
  • New York, New York
    Memorial Sloan Kettering Cancer Center
Nov 28, 2022

Liver Cell Carcinoma Trial in Houston (CATCH T cells, Cytoxan, Fludara)

Recruiting
  • Liver Cell Carcinoma
  • +7 more
  • CATCH T cells
  • +2 more
  • Houston, Texas
    Houston Methodist Hospital
Dec 19, 2022

Lymphoid Leukemia Trial in Palo Alto (Allogeneic donor-derived T-cells transduced with bivalent lentiviral vector

Not yet recruiting
  • Lymphoid Leukemia
  • Allogeneic donor-derived T-cells transduced with bivalent lentiviral vector (CD19/CD22-BBz) chimeric antigen receptor (CAR)
  • Treg CD34+ HSPC (Orca-T)
  • Palo Alto, California
    Stanford Cancer Center
Aug 17, 2022

Multiple Myeloma in Remission Trial in Shenzhen, Haikou (MM-specific universal CAR T cells)

Recruiting
  • Multiple Myeloma in Remission
  • MM-specific universal CAR T cells
  • Shenzhen, Guangdong, China
  • +1 more
Aug 23, 2023

Multiple Myeloma, Immune System Diseases Trial in Chapel Hill (CAR138 T Cells)

Recruiting
  • Multiple Myeloma
  • Immune System Diseases
  • CAR138 T Cells
  • Chapel Hill, North Carolina
    Lineberger Comprehensive Cancer Center at University of North Ca
Jan 10, 2023

Sarcoma Trial in Houston (Autologous HER2-specific T cells, Fludarabine, Cyclophosphamide)

Active, not recruiting
  • Sarcoma
  • Autologous HER2-specific T cells
  • +3 more
  • Houston, Texas
  • +1 more
Nov 21, 2022

Allogeneic Stem Cell Transplant, Viral Infection, Viral Reactivation Trial in Cincinnati (Viral specific VST Infusion)

Recruiting
  • Allogeneic Stem Cell Transplant
  • +2 more
  • Viral specific VST Infusion
  • Cincinnati, Ohio
    Cincinnati Children's Hospital Medical Center
Aug 15, 2022

Neuroblastoma Trial in Houston (GINAKIT Cells, Cyclophosphamide, Fludarabine)

Active, not recruiting
  • Neuroblastoma
  • GINAKIT Cells
  • +2 more
  • Houston, Texas
    Texas Children's Hospital
Jan 18, 2023

Prostate Carcinoma, Prostate Small Cell Neuroendocrine Carcinoma, Stage III Prostate Cancer AJCC v8 Trial in Seattle (drug,

Not yet recruiting
  • Prostate Carcinoma
  • +3 more
  • Seattle, Washington
    Fred Hutch/University of Washington Cancer Consortium
Oct 17, 2023

Leukemia, Lymphoblastic (Acute) Trial in Houston (MultiTAA-specific T cells)

Active, not recruiting
  • Leukemia, Lymphoblastic (Acute)
  • MultiTAA-specific T cells
  • Houston, Texas
  • +1 more
Aug 6, 2021

Multiple Myeloma Trial in Orange, Sacramento, Oklahoma City (STI-1492)

Recruiting
  • Multiple Myeloma
  • STI-1492
  • Orange, California
  • +2 more
Jan 12, 2023

Acute Lymphocytic Leukemia, Lymphoma Trial in New York (Biological/Genetically Modified T cells, Cyclophosphamide-based chemo)

Active, not recruiting
  • Acute Lymphocytic Leukemia
  • Lymphoma
  • Biological/Genetically Modified T cells
  • Cyclophosphamide-based chemotherapy
  • New York, New York
    Memorial Sloan Kettering Cancer Center
Jan 3, 2023

Chronic Hepatitis B Trial in Beijing (TCR-T)

Active, not recruiting
  • Chronic Hepatitis B
  • TCR-T
  • Beijing, China
    The Fifth Medical Center of PLA General Hospital
Jun 13, 2023

Leukemia, Lymphoma, Lymphoma, B-Cell Trial in New York (CAR T-Cell Infusion)

Withdrawn
  • Leukemia
  • +2 more
  • CAR T-Cell Infusion
  • New York, New York
    Memorial Sloan Kettering Cancer Center
Mar 4, 2022

Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma Trial in Seattle (biological, drug, procedure)

Completed
Has Results
  • Recurrent Plasma Cell Myeloma
  • Refractory Plasma Cell Myeloma
  • Autologous Anti-BCMA-CAR-expressing CD4+/CD8+ T-lymphocytes FCARH143
  • +3 more
  • Seattle, Washington
    Fred Hutch/University of Washington Cancer Consortium
Aug 3, 2022

High Grade B-Cell Non-Hodgkin's Lymphoma, Intermediate Grade B-Cell Non-Hodgkin's Lymphoma, Recurrent B-Cell Non-Hodgkin

Not yet recruiting
  • High Grade B-Cell Non-Hodgkin's Lymphoma
  • +3 more
  • Anti-CD19-CAR CMV-specific T-lymphocytes
  • +9 more
  • Duarte, California
    City of Hope Medical Center
Apr 5, 2023

Head Neck Cancer, Relapse, Recurrent Trial in Chapel Hill (Cyclophosphamide, Fludarabine, Cell Therapy)

Not yet recruiting
  • Head and Neck Cancer
  • +3 more
  • Chapel Hill, North Carolina
    Lineberger Comprehensive Cancer Center at University of North Ca
Oct 18, 2023

T-cell Leukemia/Lymphoma, Refractory T Lymphoblastic Leukemia/Lymphoma, Relapse/Recurrence Trial in Beijing (chimeric antigen

Recruiting
  • T-cell Leukemia/Lymphoma
  • +2 more
  • chimeric antigen receptor T cell treatment
  • Beijing, Beijing, China
    Beijing Boren Hospital
Jul 31, 2022